Global COVID-19 Recombinant Protein Vaccine Market Size, Status and Forecast 2021-2027

Preparation and immunogenicity and immunoprotection of Hib polysaccharide conjugate vaccine based on pneumococcal surface adhesive (PsaA).Methods PsaA gene recombinant protein (rPsaA) was prepared by genetic engineering, and then conjugated with Hib polysaccharide by amide condensation.The 3-week-old mice were immunized with this vaccine, and mice were inoculated with tetanus toxoid and haemophilus influenzae type B (Hib) polysaccharide conjugate vaccine (hib-tt) as controls and phosphate buffer (PBS) as blank controls.

In 2021, the global COVID-19 Recombinant Protein Vaccine market size will be US$ XX million and it is expected to reach US$ XX million by the end of 2027, with a CAGR of XX% during 2021-2027.
This report focuses on the global COVID-19 Recombinant Protein Vaccine status, future forecast, growth opportunity, key market, and key players. The study objectives are to present the COVID-19 Recombinant Protein Vaccine development in North America, Europe, Japan, China, Southeast Asia, India, etc.

Global COVID-19 Recombinant Protein Vaccine Scope and Market Size
COVID-19 Recombinant Protein Vaccine market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global COVID-19 Recombinant Protein Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Being Developed
Preclinical
Clinical I
Clinical II

Segment by Application
Pharmaceutical And Biotechnology Companies
Hospital
Academic And Research Organizations
Other

By Region
North America
Europe
Japan
China
Southeast Asia
India

By Company
GSK
Johnson & Johnson
Sanofi
Novavax
Pukang Biologic Technology
Clover Biopharmaceuticals
Suzhou Yuzhibo Biotechnology

Frequently Asked Questions